Implementing Current Susceptibility Testing Breakpoints in the Clinical Laboratory

TITLE

Implementing Current Susceptibility Testing Breakpoints in the Clinical Laboratory

OBJECTIVES

1. Describe why breakpoints are updated by CLSI and FDA

2. Evaluate breakpoints that should be prioritized by the laboratory for update

3. Discuss ways to approach breakpoint updates, including validation studies and IT changes

SPEAKER

Romney Humphries, PhD, D(ABMM)

Professor, Pathology, Microbiology and Immunology

Medical Director, Microbiology

Vanderbilt University Medical Center

Dr. Humphries received her PhD in bacteriology from the University of Calgary, Canada and a clinical and public health microbiology CPEP fellowship at UCLA. She served as the Section Chief of Clinical Microbiology for UCLA for 7 years, after which she transitioned to three years in industry, as Chief Scientific Officer at Accelerate Diagnostics. She is currently the Medical Director of Microbiology at Vanderbilt University Medical Center, where she is a Professor in the department of Pathology, Microbiology, and Immunology.

Dr. Humphries is a member of the Clinical and Laboratory Standards Institute (CLSI) Antibiotic Susceptibility Testing (AST) Subcommittee, the College of American Pathologists (CAP) Microbiology Committee, the American Society for Microbiology (ASM) Professional Practices Committee, and a member of the Infectious Diseases Society of America Diagnostics Committee. She is a on the advisory board for CARB-X. Her research interests include the development of novel tests for the diagnosis of antimicrobial resistance and infectious diseases.

SPONSOR

Accelerate Diagnostics

P.A.C.E.®

SWACM is approved as a Provider of Continuing Education Programs in Clinical Laboratory Sciences by the ASCLS P.A.C.E.® Program. Completion of this program will provide 1.0 contact hour of continuing education. SWACM programs are approved for California-licensed clinical laboratory scientists and personnel. The instructional level of this program is intermediate.